Aicuris to launch AiCubator to fight AMR
Antinfectives specialist AiCuris GmbH will launch the AiCubator, a new way to collaborate in anti-infectives and support novel approaches, at the 4th AMR Conference.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2068 entries already.
Entries by Thomas Gabrielczyk
Cell-based vaccination vs mortality-reducing therapies
Immunovative Therapies Ltd and its US subsidiary Mirror Biologics Inc. are testing a novel, T cell-based vaccination concept that might protect risk groups from new SARS-CoV-2 variants and any emerging viral pandemic in the future. However, therapies that significantly reduce the mortality rate of COVID-19 patients may be a cheaper way compared to vaccines to protect high-risk groups. UK researchers reported on the first therapy in mid-June.
AI predicts mutations underlying neurological diseases
Using data from more than 20,000 patients with neurological diseases, researchers have established an algorithm that predicts whether mutations in ion channels will cause disease.
F2G bags €50.8m financing to advance olorofim
UK-Austrian fungal infection specialist F2G Ltd has secured a €50.8m (US $60.8m) financing from new and existing investors.
Evotec receives $8.4m CARB-X funding
Evotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic.
The new role of communications in times of corona
COVID-19 has put life science research companies into the limelight. An Interview with Raimund Gabriel, founder and managing director MC Services AG, on the role of corporate communications in the corona crisis.
The end of partnering events as we know them
An ongoing crisis and evolving new working habits of industry executives call for an entirely new and up-to-date partnering format. Workarounds such as moving a partnering event’s scheduled one-on-one meetings online is neither imaginative nor does it meet the requirements of flexibility and effectiveness. The format presented here sounds the bell for a new era of pharma partnering.
BioNTech and Fosun Pharma kick off Chinese COVID-19 trials
BioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials.
Evotec partners with Secarna to develop LNA drugs
Evotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline.
Rapid test for pandemics
Rapid tests have received a lot of attention during the Coronavirus pandemic, but as the number of tests available has increased, so has the confusion around the different types and what they can deliver. What if there were laboratory quality tests that could produce a result in just a few minutes?